Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Accumulated Expenses (2022 - 2023)

60 Degrees Pharmaceuticals (SXTP) has disclosed Accumulated Expenses for 2 consecutive years, with $75000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Accumulated Expenses fell 76.92% to $75000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $75000.0, a 76.92% decrease, with the full-year FY2023 number at $75000.0, down 76.92% from a year prior.
  • Accumulated Expenses was $75000.0 for Q4 2023 at 60 Degrees Pharmaceuticals, down from $295000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $325000.0 in Q4 2022 to a low of $75000.0 in Q1 2023.